염증수용체/리간드를 타깃으로 한 비만성 염증/대사질환 제어 = Inflammatory Receptors/Ligands as a Novel Target Against Obesity-Induced Inflammation and Metabolic Diseases

다국어 초록 (Multilingual Abstract)

Obesity-induced inflammation is considered to be a potential cause of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases. Various inflammatory components involved in obesity-induced inflammation are known, but the biomolecules and mechanisms underlying the obesity-related inflammation/metabolic diseases remain to be elucidated. Cell surface membrane receptors TNFRSFs (Tumor Necrosis Factor Receptor Superfamily) and their counterpart ligands provide important inflammatory signals through their interaction, and thus have been exploited for therapeutic targets for treating various inflammatory diseases. Recent studies demonstrate that some of the inflammatory receptors/ligands are associated with obesity-induced inflammation and metabolic diseases. In this mini-review, the role of four different inflammatory receptors/ligand (CD40/CD40L, 4-1BB/4-BBL, FN14/TWEAK, HEVM/LIGHT) interactions are discussed along with their potential for therapeutic targets against obesity-related inflammation and metabolic diseases.

국문 초록 (Abstract)

비만으로 유도된 염증은 인슐린 저항성, 제2형 당뇨, 동맥경화와 같은 비만성 대사질환의 발생원인 또는 촉진자 역할을 한다. 비만성 염증반응을 매개하는 여러 가지 염증 구성요소들이 알려져 있음에도불구하고 비만성 염증/대사질환을 유도/조절하는 생체분자와 그 메커니즘에 대해서는 아직 모르는 점이 많다. 면역세포 표면에 존재하는막 수용체인 Tumor Necrosis Factor Receptor Superfamily (TNFRSF)와 그 리간드들은 염증반응 유도/조절에 중요한 신호를 제공하며, 다양한 염증성 질환의 치료를 위한 타깃 분자로 활용된다. 최근 이들 염증수용체/리간드가 비만성 지방조직 염증반응을 조절하며, 이들 분자들의 상호작용의 차단이 비만성 염증/대사질환의 개선을 가져온다고 보고되고 있다. 본 미니리뷰에서는 비만성 염증/대사질환에 관여하는 네 종류의 염증수용체/리간드(CD40/CD40L, 4-1BB/4-BBL,FN14/TWEAK, HEVM/LIGHT)들에 대해 살펴보고, 이들 분자들이비만성 염증 및 대사질환 제어를 위한 타깃이 될 가능성에 대해 검토해 보았다.

참고문헌 (Reference)

1 Kim CS, "Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice" 16 : 1261-1269, 2008

2 Vendrell J, "Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia" 95 : 2983-2992, 2010

3 Law CL, "Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges" 647 : 8-36, 2009

4 Croft M., "The role of TNF superfamily members in T-cell function and diseases" 9 : 271-285, 2009

5 Maymó-Masip E, "The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα" 98 : E1323-E1333, 2013

6 Maymó-Masip E, "The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα" 98 : E1323-E1333, 2013

7 Poggi M, "The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes" 52 : 1152-1163, 2009

8 Kim CS, "The immune signaling molecule 4-1BB stimulation reduces adiposity, insulin resistance, and hepatosteatosis in obese mice" 151 : 4725-4735, 2010

9 Pierer M, "The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis" 46 : 1063-1070, 2007

10 Vendrell J, "TWEAK: a new player in obesity and diabetes" 4 : 488-, 2013

11 Burkly LC, "TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses" 244 : 99-114, 2011

12 Blanco-Colio LM, "TWEAK/Fn14 Axis: a promising target for the treatment of cardiovascular diseases" 5 : 3-, 2014

13 Croft M, "TNF superfamily in inflammatory disease: translating basic insights" 33 : 144-152, 2012

14 Yilmaz MI, "Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease" 4 : 1716-1723, 2009

15 Kralisch S, "Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease" 199 : 440-444, 2008

16 Michaelson JS, "Role of TWEAK in lupus nephritis: a bench-to-bedside review" 39 : 130-142, 2012

17 Yu R., "Response to Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders" 60 : 3159-3168, 2011

18 Shui JW, "Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling" 89 : 517-523, 2011

19 Lievens D, "Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis" 116 : 4317-4327, 2010

20 Weisberg SP, "Obesity is associated with macrophage accumulation in adipose tissue" 112 : 1796-1808, 2003

21 Yu R, "Mesenteric adipose tissuederived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice" 14 : 1353-1362, 2006

22 An MM, "Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through blocking LIGHT/HVEM signaling" 29 : 2025-2030, 2006

23 Tu TH, "Levels of 4-1BB transcripts and soluble 4-1BB protein are elevated in the adipose tissue of human obese subjects and are associated with inflammatory and metabolic parameters" 2014

24 Kim HM, "LIGHT/TNFSF14 enhances adipose tissue inflammatory responses through its interaction with HVEM" 585 : 579-584, 2011

25 Kang YM, "LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes" WILEY-LISS 56 : 1106-1117, 2007

26 Bassols J, "LIGHT is associated with hypertriglyceridemia in obese subjects and increased cytokine secretion from cultured human adipocytes" 34 : 146-156, 2010

27 Heo SK, "LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM" FEDERATION AMER SOC EXP BIOL 79 : 330-338, 2006

28 Sandberg WJ, "Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis" 104 : 60-68, 2009

29 Yu R, "Inflammatory components of adipose tissue as target for treatment of metabolic syndrome" 61 : 95-103, 2009

30 Hotamisligil GS, "Inflammation and metabolic disorders" 444 : 860-867, 2006

31 Vinay DS, "Immunotherapy of cancer with 4-1BB" 11 : 1062-1070, 2012

32 Kwon BS, "Immune responses in 4-1BB (CD137)-deficient mice" 168 : 5483-5490, 2002

33 Wang C, "Immune regulation by 4-1BB and 4-1BBL: complexities and challenges" 229 : 192-215, 2009

34 Blanco-Colio LM, "Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis" 27 : 916-922, 2007

35 Gregor MF, "Hotamisligil GS. Inflammatory mechanisms in obesity" 29 : 415-445, 2011

36 Wellen KE, "Hotamisligil GS. Inflammation, stress, and diabetes" 115 : 1111-1119, 2005

37 Kim HJ, "HVEM-deficient mice fed a high-fat diet are protected from adipose tissue inflammation and glucose intolerance" 585 : 2285-2290, 2011

38 Ju SA, "Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice" 122 : 2784-2790, 2008

39 Bukczynski J, "Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L" 175 : 6378-6389, 2005

40 Arribillaga L, "Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus" 23 : 3493-3499, 2005

41 Visser M, "Elevated C-reactive protein levels in overweight and obese adults" 282 : 2131-2135, 1999

42 Kim CS, "Deficiency for costimulatory receptor 4-1BB protects against obesityinduced inflammation and metabolic disorders" 60 : 3159-3168, 2011

43 Chorianopoulos E, "Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure" 11 : 1050-1056, 2009

44 Niu L, "Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice" 178 : 4194-4213, 2007

45 Croft M, "Clinical targeting of the TNF and TNFR superfamilies" 12 : 147-168, 2013

46 Bassols J, "Characterization of herpes virus entry mediator as a factor linked to obesity" 18 : 239-246, 2010

47 Missiou A, "CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease" 103 : 788-796, 2010

48 Wolf D, "CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies" 7 : e33026-, 2014

49 Poggi M, "CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice" 31 : 2251-2260, 2011

50 Guo CA, "CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance" 304 : E951-E963, 2013

51 Peters AL, "CD40 and autoimmunity: the dark side of a great activator" 21 : 293-300, 2009

52 Olofsson PS, "CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice" 117 : 1292-1301, 2008

53 Jeon HJ, "CD137 (4–1BB) deficiency reduces atherosclerosis in hyperlipidemic mice" 121 : 1124-1133, 2010

54 Schwarz H, "Biological activities of reverse signal transduction through CD137 ligand" 77 : 281-286, 2005

55 Carrero JJ, "Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients" 4 : 110-118, 2009

56 Tu TH, "4-1BB/4-1BBL interaction promotes obesity-induced adipose inflammation by triggering bidirectional inflammatory signaling in adipocytes/ macrophages" 2012 : 972629-, 2012

57 Lee SW, "4-1BB as a therapeutic target for human disease" 647 : 120-129, 2009